收费全文 | 11919篇 |
免费 | 1022篇 |
国内免费 | 34篇 |
耳鼻咽喉 | 99篇 |
儿科学 | 402篇 |
妇产科学 | 327篇 |
基础医学 | 1719篇 |
口腔科学 | 202篇 |
临床医学 | 1605篇 |
内科学 | 2057篇 |
皮肤病学 | 138篇 |
神经病学 | 1335篇 |
特种医学 | 266篇 |
外科学 | 1227篇 |
综合类 | 134篇 |
一般理论 | 15篇 |
预防医学 | 1804篇 |
眼科学 | 198篇 |
药学 | 842篇 |
中国医学 | 5篇 |
肿瘤学 | 600篇 |
2023年 | 148篇 |
2022年 | 168篇 |
2021年 | 380篇 |
2020年 | 276篇 |
2019年 | 410篇 |
2018年 | 422篇 |
2017年 | 354篇 |
2016年 | 396篇 |
2015年 | 343篇 |
2014年 | 473篇 |
2013年 | 657篇 |
2012年 | 910篇 |
2011年 | 932篇 |
2010年 | 478篇 |
2009年 | 376篇 |
2008年 | 684篇 |
2007年 | 705篇 |
2006年 | 618篇 |
2005年 | 559篇 |
2004年 | 511篇 |
2003年 | 487篇 |
2002年 | 459篇 |
2001年 | 135篇 |
2000年 | 118篇 |
1999年 | 127篇 |
1998年 | 94篇 |
1997年 | 66篇 |
1996年 | 72篇 |
1995年 | 55篇 |
1994年 | 57篇 |
1993年 | 56篇 |
1992年 | 100篇 |
1991年 | 90篇 |
1990年 | 101篇 |
1989年 | 81篇 |
1988年 | 88篇 |
1987年 | 71篇 |
1986年 | 83篇 |
1985年 | 94篇 |
1984年 | 64篇 |
1983年 | 58篇 |
1982年 | 29篇 |
1981年 | 34篇 |
1979年 | 46篇 |
1978年 | 37篇 |
1977年 | 33篇 |
1975年 | 39篇 |
1974年 | 41篇 |
1973年 | 31篇 |
1972年 | 32篇 |
Methods: A retrospective cohort design and data from two US healthcare claims repositories were employed. The study population included patients who had non-metastatic cancer of the breast, colon/rectum, lung or ovaries, or non-Hodgkin’s lymphoma (NHL), and who received myelosuppressive chemotherapy regimens with an intermediate/high risk for FN. For each patient, the first cycle of the first course was characterized in terms of PP-CSF use and FN episodes. Crude incidence proportions for PP-CSF and FN during the first cycle were estimated by calendar quarter (2010–2016); multivariable logistic regression models were used to estimate quarter-specific adjusted mean probabilities of FN by PP-CSF use.
Results: The study population totaled 142,730 patients with breast cancer (61%), colorectal cancer (14%), NHL (11%), ovarian cancer (10%) or lung cancer (5%). PP-CSF use increased from 52% in 1Q2010 to 58% in 4Q2016; pegfilgrastim was the most commonly used agent (>96% across quarters). PP-CSF administration on the same day as chemotherapy ranged from 8 to 11% until 1Q2015, and increased to 64% by 4Q2016. Adjusted incidence proportions for FN in the first chemotherapy cycle ranged from 2.7% (95% CI: 2.3–3.0) to 3.7% (95% CI: 3.1–4.3) among those who did not receive PP-CSF, and was 2.6% (95% CI: 2.5–2.7) across quarters among those who received PP-CSF.
Conclusions: Although the use of PP-CSF is commonplace in current US clinical practice, underutilization in cancer patients receiving chemotherapy regimens with an intermediate/high risk for FN may still be an issue. Use of same-day PP-CSF increased markedly from the end of 2015, although this finding reflects (at least in part) increased uptake of pegfilgrastim delivered via an on-body injector as well as the recent change in clinical practice guidelines. Overall, patients receiving PP-CSF appear to have a lower risk of FN during the first cycle of chemotherapy. 相似文献